Connect with us

Technology

Symphony Robotics Welcomes Neurosurgery Leader Dr. Neil A. Martin as Chief Medical Officer to Revolutionize Glioblastoma Treatment with First-Ever MRI-Steerable Micro-Robotics

Published

on

MIAMI, April 25, 2025 /PRNewswire/ — Symphony Robotics, a pioneer in advanced neurosurgical micro-robotics, today announced the appointment of renowned neurosurgeon Dr. Neil A. Martin as its Chief Medical Officer (CMO). In this pivotal role, Dr. Martin will lead the advancement of the company’s groundbreaking, engine-free, nonlinear, flexible micro-robotic system, poised to transform the treatment landscape for Glioblastoma Multiforme (GBM).

Symphony Robotics, a pioneer in advanced neurosurgical micro-robotics, appoints renowned neurosurgeon as CMO.

“Glioblastoma remains the most treatment-resistant and lethal primary brain tumor, with a median survival of only 14-16 months following maximal safe resection plus adjuvant chemoradiotherapy, and a five-year survival rate below 7%,” stated Dr. Martin. “Despite significant advances in molecular characterization and targeted therapeutics, meaningful improvements in clinical outcomes have remained elusive.”

Early preclinical studies using anatomically accurate GBM models under real-time MRI guidance have shown that Symphony Robotics’ platform achieves significant improvements in maneuverability, resulting in up to 3 times the volumetric coverage when compared with existing technologies, with millimeter-level precision, crucial for protecting critical healthy brain tissue while maximizing tumor removal.

Dr. Martin continued, “Symphony Robotics is positioned to transform the treatment paradigm by substantially extending the capabilities of Laser Interstitial Thermal Therapy (LITT) in GBM—potentially tripling the ablation volume achievable through its steerability after single-site minimally invasive insertion. Our initial objective is to significantly enhance the efficacy of LITT through precise, nonlinear navigation to previously unreachable tumor margins, even in large and irregular tumors. We are implementing an aggressive translational research pipeline for developing applications to accompany and synergize with thermal ablation, including targeted drug and immunotherapy delivery systems for precision neuro-oncology.”

“Symphony Robotics is built on a foundation of rigorous research and a robust intellectual property portfolio, supported by grants from the National Institutes of Health (NIH) and the National Science Foundation (NSF), and exclusively licensed from Case Western Reserve University,” said Mordechai (Moty) Avisar, Founder and CEO of Symphony Robotics. “Welcoming Dr. Martin—a visionary leader in neurosurgery—to our team marks a pivotal milestone that will accelerate our mission to revolutionize GBM treatment. By harnessing the power of artificial intelligence, our platform is poised to optimize therapy and deliver this life-changing technology to patients worldwide.”

The company is currently establishing collaborations with leading neurosurgical centers to initiate beta site testing later this year, ensuring thorough clinical assessment in diverse patient populations and anatomical scenarios.

CONTACT: info@symphonyrobotics.health
LinkedIn: https://www.linkedin.com/company/symphonyrobotics/

Symphony Robotics is developing advanced medical technology focused on transforming neurosurgical precision through its engine-free, nonlinear, flexible, micro-robotic platform, leveraging AI to optimize GBM treatment. Recognizing the limitations of current techniques in treating complex intracranial pathologies, particularly aggressive cancers like GBM and medically refractory epilepsy, the company aims to improve surgical outcomes by enabling more precise and extensive tumor ablation, minimizing damage to healthy brain tissue, and ultimately improving both patient survival and quality of life. The integration of real-time MRI guidance with advanced robotics and computational navigation algorithms allows their innovative platform to access and treat previously unreachable areas within the brain. Disclaimer: Symphony Robotics’ products are not approved by the Food and Drug Administration (FDA) and are not available for commercial distribution or clinical use.

View original content to download multimedia:https://www.prnewswire.com/news-releases/symphony-robotics-welcomes-neurosurgery-leader-dr-neil-a-martin-as-chief-medical-officer-to-revolutionize-glioblastoma-treatment-with-first-ever-mri-steerable-micro-robotics-302438762.html

SOURCE Symphony Robotics

Continue Reading

Technology

3M announces collaboration with GSEO to advance Expanded Beam Optical manufacturing and development

Published

on

By

ST. PAUL, Minn., Oct. 19, 2026 /PRNewswire/ — 3M (NYSE: MMM) today announced a collaboration with Genius Electronic Optical Co., Ltd. (GSEO, Taiwan: 3406), an optical technology company, to advance technology development and manufacturing for 3M’s Expanded Beam Optical (EBO) solutions. In support of these efforts, 3M expects to make a strategic investment to acquire approximately 4.7% of GSEO’s common shares as part of the company’s private placement of newly issued shares, subject to customary closing conditions.

The collaboration brings together 3M’s EBO technology leadership, optical interconnect expertise, materials science, manufacturing scale and customer relationships with GSEO’s precision optics manufacturing capabilities and production scale. Together, the companies aim to support EBO commercialization and long-term capacity expansion to meet growing demand from hyperscale data centers and other advanced connectivity applications.

“3M is investing in capabilities and partnerships that can accelerate innovation for our customers,” said William Brown, 3M Chairman and CEO. “By selecting GSEO as a manufacturing partner and investing in the company, we are strengthening the path to scale next-generation optical connectivity solutions for high-performance data center infrastructure.”

GSEO’s existing precision optics manufacturing capabilities and technical development experience are expected to support manufacturing readiness for 3M’s EBO ferrules, co-packaged optics solutions and related optical interconnect applications. The collaboration is part of 3M’s broader EBO ecosystem strategy, which includes continued work with customers and partners across the optical interconnect market.

“GSEO is pleased to expand its relationship with 3M as we work together to advance optical interconnect solutions for next-generation data center infrastructure,” said Micro Kuo, GSEO CEO and President. “This collaboration brings together complementary technology and manufacturing strengths to support continued innovation and help meet the performance demands of high-growth connectivity markets.”

3M expects the strategic investment to close in the fourth quarter of 2026, subject to customary closing conditions.

Forward-Looking Statements
Certain statements in this release are considered “forward-looking statements” under the federal securities laws, including the Private Securities Litigation Reform Act of 1995, as amended, and are intended to enjoy the protection of those laws. Forward-looking statements may appear throughout this release and are typically identified by the words “aim,” “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “evaluate,” “expect,” “forecast,” “future,” “goal,” “guidance,” “impact,” “initial,” “intend,” “likely,” “may,” “outlook,” “plan,” “possible,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “strategy,” “target,” “will,” “would,” and other words that are similar to, or have the opposite meanings of, those words. Forward-looking statements speak only as of the date they are made, 3M assumes no duty to update those statements, and readers are cautioned not to place undue reliance on any of those statements. Forward-looking statements are based on certain assumptions and expectations of future events and trends that are subject to risks and uncertainties, including those described in Part I, Item 1A, “Risk Factors” of 3M’s Form 10-K for the year ended December 31, 2025.

About 3M
3M (NYSE: MMM) is focused on transforming industries around the world by applying science and creating innovative, customer-focused solutions. Our multi-disciplinary team is working to solve tough customer problems by leveraging diverse technology platforms, differentiated capabilities, global footprint, and operational excellence. Discover how 3M is shaping the future at 3M.com/news.

Contacts
3M
Investor Contact:
Diane Farrow, 612-202-2449
Media Contact:
3MNews@mmm.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/3m-announces-collaboration-with-gseo-to-advance-expanded-beam-optical-manufacturing-and-development-302913170.html

SOURCE 3M Company

Continue Reading

Technology

Scott Vicknair Personal Injury Lawyers Announces Second Annual Operation Fur-Ever Home Pet Adoption Event at Lafreniere Park

Published

on

By

NEW ORLEANS, Oct. 19, 2026 /PRNewswire/ — Scott Vicknair Personal Injury Lawyers is excited to announce the return of its second annual Operation Fur-Ever Home, a free community pet adoption event taking place on Saturday, November 14, 2026, from 9:00 a.m. to 11:00 a.m. at Lafreniere Park in Metairie, Louisiana.

The free, family-friendly event will give attendees the opportunity to meet adoptable pets from local animal shelters, learn about responsible pet ownership, and potentially welcome a new furry companion into their homes. Those who preregister for the event will also be entered for a chance to win a Soundcore speaker and a free pet adoption.

“Last year’s event was everything we hoped it would be, and we are incredibly excited to bring Operation Fur-Ever Home back for a second year,” said David Vicknair, founding partner of Scott Vicknair Personal Injury Lawyers. “There is something special about watching a family meet a pet that could become part of their lives for years to come. We wanted to create another opportunity to make those connections while supporting the organizations that work tirelessly to care for animals in our community.”

Building on the success of the first event, this year’s event continues the firm’s commitment to supporting local animal shelters and creating meaningful opportunities for families throughout Southeast Louisiana.

“Giving back to our community has always been an important part of who we are as a firm,” said Vicknair. “Whether we are helping students prepare for school, recognizing deserving teachers, or supporting local animal shelters, our goal is to make a positive difference in the communities we serve.”

Operation Fur-Ever Home is free and open to the public. Families, animal lovers, and anyone interested in adopting a pet are encouraged to attend and preregister.

About Scott Vicknair Personal Injury Lawyers

Scott Vicknair Personal Injury Lawyers is a New Orleans-based personal injury firm committed to providing exceptional legal representation while also investing in the communities it serves. Their experienced team of dedicated attorneys specializes in car accidents, personal injury, and wrongful death cases in New Orleans. With diverse personal and professional backgrounds, they craft legal strategies tailored to each client’s specific case and needs.

View original content:https://www.prnewswire.com/news-releases/scott-vicknair-personal-injury-lawyers-announces-second-annual-operation-fur-ever-home-pet-adoption-event-at-lafreniere-park-302913183.html

SOURCE Scott Vicknair Personal Injury Lawyers

Continue Reading

Technology

Can we produce low-cost omega-3s without relying on fish?

Published

on

By

GOLD COAST, Australia, Oct. 19, 2026 /PRNewswire/ — Southern Cross University researchers are aiming to halve the cost of producing omega-3 supplements to make these essential nutrients more accessible to pregnant women and infants in low-income countries, backed by the University’s first-ever grant from The Gates Foundation.

The research takes a novel approach: rather than relying on fish oil, the team is going closer to the original source of omega-3. Fish don’t produce omega-3 themselves – they accumulate it from marine microorganisms lower in the food chain.

Led by Professor Dirk Erler from Southern Cross University’s Faculty of Science and Engineering, the team is investigating how these naturally omega-3-producing microorganisms can be grown more cheaply through precision fermentation, including the use of agricultural and food-processing by-products as a source of fermentation sugar.

Omega-3 is an important nutrient during pregnancy and early life, supporting brain and nervous system development in babies. But the cost of supplements remains a significant barrier to access in many low-income countries.

“The main barrier for the uptake of omega-3s as supplements in pregnant women is the cost,” Professor Erler said.

“The whole objective of our project is to reduce that cost and make omega-3 supplements more available.”

The research team at Southern Cross University, which includes biomedical scientist Dr Nedeljka Rosic, Dr Shane McIntosh, postdoctoral researcher Dr Jasmine Haskell and PhD researcher Michael Ingram, is focused on growing omega-3-producing marine microorganisms known as thraustochytrids – or ‘throstys’ for short.

“By growing those microorganisms on land through precision fermentation, we have an alternative way of producing omega-3s that is both reliable and highly targeted,” Professor Erler said.

Precision fermentation allows the researchers to grow thraustochytrids under controlled conditions to produce omega-3 oils. The team is investigating whether expensive feedstocks used in the process can be replaced with lower-cost agricultural and food-processing by-products, helping drive down the overall cost of production.

The approach could also reduce reliance on wild-caught fish as a source of omega-3 oil and create a more reliable, scalable, and local supply.

For biomedical scientist Dr Nedeljka Rosic, the production challenge is ultimately about what greater access to omega-3 could mean for women and babies.

“As a biomedical scientist, my purpose is to find ways to use science to improve people’s health,” Dr Rosic said.

“This project is important because it aims to improve the health of pregnant women and children and reduce preterm births through simple dietary improvements.”

View original content to download multimedia:https://www.prnewswire.com/news-releases/can-we-produce-low-cost-omega-3s-without-relying-on-fish-302893631.html

SOURCE Southern Cross University

Continue Reading

Trending